Analysts tap Amgen, Celgene as potential 2012 dealmakers

Analysts are saying the world's biggest biotechs, including Amgen ($AMGN) and Celgene ($CELG), are likely to scout for big acquisitions this year as they seek to revive growth and refill pipelines, Bloomberg reports. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.